Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667236 · ClinicalTrials.gov registry record · Phase 3
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
A Phase 3 study of Seborrheic Keratosis, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 1
- Study location
NCT02667236 is a Phase 3 study of Seborrheic Keratosis that has completed, run by Aclaris Therapeutics. The registered enrollment target is 450 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02667236, a Phase 3 study of Seborrheic Keratosis, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.
Conditions Studied
Interventions
- DRUG A-101 Solution
- OTHER Vehicle Solution
Study Locations (1)
Pennsylvania
- Aclaris Therapeutics, Inc. - Malvern
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02667236
The ClinicalTrials.gov registry entry for NCT02667236 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seborrheic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which A-101 Solution is the first listed.
NCT02667236 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02667236 about?
NCT02667236 is a clinical study titled "A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.". This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.
What is the current status of trial NCT02667236?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2016-01. Estimated completion is 2016-10.
What conditions does trial NCT02667236 study?
This clinical trial studies the following conditions: Seborrheic Keratosis.
What interventions are being tested in trial NCT02667236?
The interventions under investigation include: A-101 Solution (DRUG), Vehicle Solution (OTHER).
Who is sponsoring clinical trial NCT02667236?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02667236 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seborrheic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.